Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Barclays analyst Etzer Darout maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and lowers the price target from $...
RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0...
Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and raises the price target from $...
HC Wainwright & Co. analyst Emily Bodnar maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and raises the price targe...
Guggenheim analyst Yatin Suneja initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Buy rating and announces Price ...
RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT"), a clinical-stage immunology-based biopharmaceutical company focused on ...
Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and raises the price target from $...
